Susanne Staer

This author has written 409 articles

York University becomes 17th Member of MaRS Innovation

MaRS Innovation to act as commercialization agent for York’s life sciences and technology discoveries, leveraging new potential for York’s existing $70 million in research initiatives

TORONTO, May 9, 2011 – York University has become the latest member of MaRS Innovation, the commercialization agent for many leading Toronto-based universities, hospitals and research institutes.

Stan Shapson, vice-president Research & Innovation, York University
Stan Shapson, Vice-President Research & Innovation, York University

“York has become one of Canada’s fastest-growing centres for research and innovation,” said Stan Shapson, vice-president Research & Innovation at York University. “We typically get 10 to 20 discovery disclosures a year. Joining MaRS Innovation allows us to deliver the most competitive commercialization services to the researchers making these discoveries. We’re confident that membership in MaRS Innovation will boost that number and accelerate the commercialization of York’s most promising research.”

Earlier this year, York University launched its Innovation York office. Based in York Region, Innovation York works with other partner organizations in the Markham Convergence Centre to build upon research partnerships between York researchers and life science and technology companies based in York Region and the Greater Toronto Area. It’s also making York’s research and infrastructure more accessible to industry, government agencies and community partners.

Continue Reading

Vasculotide: sanofi-aventis, Sunnybrook and MI – Article in the Globe and Mail

A discovery that could help millions of diabetics worldwide is the subject of a lucrative pharmaceutical deal that will enrich the Toronto hospital that created it – part of a growing trend of selling science to help shore up Canada’s troubled health-care system.

Tuesday’s agreement between Sanofi-Aventis and Sunnybrook Health Sciences Centre on a wound-healing molecule demonstrates how entrepreneurial hospitals can become when the very sustainability of medicare is in question.

But the licensing deal with one of the world’s biggest drug companies is also savvy medically. Until recently, some hospitals were reticent to capitalize on their discoveries, seeing commercialization as unsavoury, but now many believe it’s one of the quickest ways to get a drug to their patients.

Continue Reading

How VitalHub Corp. Uses iPhones® To Help Health Care

VitalHub Corp Logo: Patient information made easyTORONTO, ON (Jan. 25, 2011) —Doctors, nurses and administrators can now access electronic health applications on mobile, hand-held technology through VitalHub Corp..

The unique start-up company was spun-off from mobile health technologies developed  Toronto’s Mount Sinai Hospital, thanks in part to $300,000 in seed financing from MaRS Innovation that will give it a crucial head start in the fiercely competitive mobile IT health sector.

MaRS Innovation invests in the most commercially promising discoveries emerging from its member institutions, which include 16 of Toronto’s leading universities, hospitals (such as Mount Sinai) and research institutions. This funding commitment rounds out a sizeable seed round of financing for VitalHub.

Continue Reading

$15M Funding announcement for CCRM

Centre for the Commercialization of Regenerative MedicineAs part of MaRS Innovation’s strategy to bundle technologies, our first initiative focused on regenerative medicine and creating the Centre for Commercialization of Regenerative Medicine (CCRM) located in Toronto, Ontario.

We are pleased that these efforts have been recognized by the Government of Canada‘s National Centres of Excellence (NCE) program, which recently announced a $15 million funding grant for CCRM through the Centres of Excellence for Commercialization and Research.

Continue Reading

Wound Healing Technology Exclusive Rights Deal with Cardium Therapeutics

TORONTO
 (October
 14,
 2010)
 –
 Of
 the
 approximately
 300
 million
 people
 around
 the
 world
 who
 are
 diabetics,
 45
 million
 of
 them
 develop 
foot
 ulcers 
that 
bleed
 – 
and 
the 
infection
 from
 those 
ulcers
 can 
spread.

University of Toronto
University of Toronto

Working
 to
 halt
 this
 is
 Dr.
 Ping
 Lee,
 a
 professor
 at
 the
 University
 of
 Toronto’s (U of T)
 Leslie
 Dan
 Faculty
 of
 Pharmacy
 and
 GlaxoSmithKline
 chair
 in
 Pharmaceutics
 and 
Drug 
Delivery.
 He 
and 
his
 team
 have 
created 
a 
new 
sustained‐release
 form
 of
 nitric 
oxide 
(NO) 
that
 can
 not
 only
 stop 
the 
infections 
at
 wound
sites, 
but
 also
 has
 the
 potential 
to
speed
 up
 wound‐healing.

Still,
 the
 technology
 may
 have
 stayed
 on
 the
 shelf,
 even
 with
 three
 years
 worth
 of
 data
 demonstrating
 therapeutic
 relevance.
 The
 ultimate
 success
 of
 the
 technology
 is
 due
 to
 an
 effective
 collaboration
 between
 Dr.
 Lee,
 the
 Innovations
 and
 Partnerships
 Office
 (IPO)
 at
 U
 of
 T
 and
 MaRS
 Innovation (MI).
 Lee
 worked
 with
 IPO
 and
 MI to
 formulate
 a
 development
 plan
 in
 consultation
 with 
numerous 
industry
 advisors.

Continue Reading

Quick Links

Contact Us

Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca

© CopyrightTIAP 2024 - All Rights Reserved | Site Map | CASL Policy | Privacy Policy | AODA Compliance
Twitter Linkedin
Back To Top